表皮生长因子受体敏感突变肺癌靶向治疗原发性耐药机制的研究进展

The research progress in the mechanism of primary resistance in targeted therapy for lunng cancer with epidermal growth factor receptor-sensitive mutations

针对伴有表皮生长因子受体(EGFR)敏感突变的晚期非小细胞肺癌, 小分子靶向药物表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)治疗效果明确, 是目前的标准治疗方法。然而, 部分患者在初始治疗时即出现原发性耐药。本文就EGFR敏感突变的晚期非小细胞肺癌患者原发性耐药可能机制展开讨论与总结, 以期为临床治疗决策提供参考。

Small molecule targeted drug epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs)have been established as the standard treatment for advanced non-small cell lung cancer(NSCLC)with EGFR sensitive mutations.Nevertheless,a subset of patients exhibit primary resistance to EGFR-TKIs during initial therapy.This review aims to summarize the potential mechanisms underlying primary drug resistance in advanced NSCLC patients with EGFR sensitive mutations,with the intention of offering valuable insights for clinical treatment strategies.